How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy. (19th October 2017)

• Record Type: Journal Article
• Authors: Rea, Delphine; Mahon, François‐Xavier
• Is Part Of: British journal of haematology. Volume 180:Number 1(2018)
• Page Start: 24
• Page End: 32
• Publication Date: 2017-10-19
• Subjects: chronic myeloid leukaemia -- clinical aspects -- therapy -- TKI discontinuation -- relapse; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.14973
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: During the last 10 years, clinical trials formally demonstrated that about 50% of patients with chronic phase (CP) chronic myeloid leukaemia (CML) who achieve and maintain deep molecular responses for a prolonged period of time during treatment with imatinib or new generation tyrosine kinase inhibitors (TKIs) may successfully stop their anti‐leukaemic therapy. Based on the accumulated knowledge from abundant clinical trial experience, TKI discontinuation is becoming an important goal to achieve and is about to enter clinical practice. This review focuses on relapse definition, laboratory tests to identify relapse and relapse management after TKI discontinuation.